TheNote
FDA Approves First Therapy to ... Note
GooglePlay AppStore
FDA | What's New

FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy

The U.S. Food and Drug Administration today approved Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment. Isembyld is the first therapy approved for SMA that dire
http://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy fda.gov
RSS Hunter RSS Hunter • Sep 11